P-27/HP endolysin as antibacterial agent for antibiotic resistant Staphylococcus aureus of human infections

Current Microbiology

Volumn 63, Issue 1, 2011, Pages 39-45

  Gupta, Ragini ^a,b,c   Prasad, Yogendra ^b  

^a INDIAN VETERINARY RESEARCH INSTITUTE   (India)

^b M J P ROHILKHAND UNIVERSITY   (India)

^c INDIAN INSTITUTE OF TECHNOLOGY KANPUR   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ENDOLYSIN HP; ENDOLYSIN P 27; POLYPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PH; PRIORITY JOURNAL; SPLEEN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ENDOPEPTIDASES; ENZYME STABILITY; FEMALE; HUMANS; MALE; MICE; SEWAGE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS PHAGES; VIRAL PROTEINS;

ANIMALIA; MUS; STAPHYLOCOCCUS AUREUS;

EID: 79959752636     PISSN: 03438651     EISSN: 14320991     Source Type: Journal    
DOI: 10.1007/s00284-011-9939-8     Document Type: Article

References (24)

1. Borysowski J, Weber-Dabrowska B, Gorski A (2006) Bacteriophage endolysins as a novel class of antibacterial agents. Exp Biol Med (Maywood) 231(4):366-377
2. Capparelli R, Parlato M, Borriello G et al (2007) Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 51(8):2765-2773. doi:10.1128/AAC.01513-06 (Pubitemid 47206211)
3. Casey AL, Lambert PA, Elliott TSJ (2007) Staphylococci. Int J Antimicrob Agents 29(3):S23-S32. doi:10.1016/S0924-8579(07)72175-1 (Pubitemid 47058921)
4. Chambers HF (2005) Community-associated MRSA - resistance and virulence converge. New Engl J Med 352(14):1485-1487
5. Fischetti VA (2010) Bacteriophage endolysins: a novel antiinfective to control Gram-positive pathogens. Int J Med Microbiol 300(6):357-362. doi:10.1016/j.ijmm.2010.04.002
6. Górski A, Miedzybrodzki R, Borysowski J, Weber-Dabrowska B, Lobocka M, Fortuna W, Letkiewicz S, Zimecki M, Filby G (2009) Bacteriophage therapy for the treatment of infections. Curr Opin Investig Drugs 10(8):766-774
7. Gupta R, Prasad Y (2011) Efficacy of polyvalent bacteriophage P-27/HP to control multidrug resistant Staphylococcus aureus associated with human infections. Curr Microbiol 62(1):255-260. doi:10.1007/s00284-010-9699-x
8. Hermoso JA, García JL, García P (2007) Taking aim on bacterial pathogens: from phage therapy to enzybiotics. Curr Opin Microbiol 10(5):461-472. doi:10.1016/j.mib.2007.08.002 (Pubitemid 350064581)
9. Jado I, Lopez R, Garcia E, Fenoll A, Casal J, Garcia P (2003) Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrob Chemother 52(6):967-973. doi:10.1093/jac/dkg485 (Pubitemid 38008417)
10. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST (2010) Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol 11(1):69-86
11. Loessner MJ (2005) Bacteriophage endolysins - current state of research and applications. Curr Opin Microbiol 8(4):480-487. doi:10.1016/j.mib.2005.06. 002
12. Lowy FD (1998) Staphylococcus aureus infections. N Engl J Med 339(8):520-532
13. Lowy FD (2003) Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 111(9):1265-1273. doi: 10.1172/JCI200318535
14. Manoharadas S, Witte A, Blasi U (2009) Antimicrobial activity of a chimeric enzybiotic towards Staphylococcus aureus. J Biotechnol 139(1):118-123. doi:10.1016/j.jbiotec.2008.09.003
15. Matsuzaki S, Yasuda M, Nishikawa H, Kuroda M, Ujihara T, Shuin T, Shen Y, Jin Z, Fujimoto S, Nasimuzzaman MD, Wakiguchi H, Sugihara S, Sugiura T, Koda S, Muraoka A, Imai S (2003) Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis 187(4):613-624. doi:10.1086/374001 (Pubitemid 36250025)
16. Nelson D, Loomis L, Fischetti VA (2001) Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA 98(7):4107-4112. doi:10.1073/pnas.061038398 (Pubitemid 32249906)
17. O'Flaherty S, Ross RP, Coffey A (2009) Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol Rev 33(4):801-819. doi:10.1111/j.1574-6976.2009.00176.x
18. Obeso JM, Martinez B, Rodriguez A, Garcia P (2008) Lytic activity of the recombinant staphylococcal bacteriophage UH5 endolysin active against Staphylococcus aureus in milk. Int J Food Microbiol 128:212-218. doi:10.1016/j.ijfoodmicro.2008.08.010
19. Parisien A, Allain B, Zhang J, Mandeville R, Lan CQ (2008) Novel alternatives to antibiotics: bacteriophages, bacterial cell wall hydrolases, and antimicrobial peptides. J Appl Microbiol 104(1):1-13. doi:10.1111/j.1365-2672. 2007.03498.x (Pubitemid 350265294)
20. Payne D, Tomasz A (2004) The challenge of antibiotic resistant bacterial pathogens: the medical need, the market and prospects for new antimicrobial agents. Curr Opin Microbiol 7(5):435-438. doi:10.1016/j.mib.2004.08.017 (Pubitemid 39297121)
21. Service RF (2004) Orphan drugs of the future? Science 303(5665):1798. doi:10.1126/science.303.5665.1798
22. Sonstein SA, Hammel JM, Bondi A (1971) Staphylococcal bacteriophage-associated lysin: a lytic agent active against Staphylococcus aureus. J Bacteriol 107(2):499-504
23. Takác M, Bläsi U (2005) Phage P68 virion-associated protein 17 displays activity against clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother 49(7):2934-2940. doi: 10.1128/AAC.49.7.2934-2940. 2005
24. Witzenrath M, Schmeck B, Doehn JM, Tschernig T, Zahlten J, Loeffler JM, Zemlin M, Müller H, Gutbier B, Schütte H, Hippenstiel S, Fischetti VA, Suttorp N, Rosseau S (2009) Systemic use of the endolysin Cpl-1 rescues mice with fatal Pneumococcal pneumonia. Crit Care Med 37(2):642-649